The Paragard Lawsuit: A Deep-Dive Evidentiary Guide To MDL 2974

Quick Answer:

A claimant can establish a viable Paragard Lawsuit by documenting that the non-hormonal copper intrauterine device (IUD) underwent structural failure or breakage during explantation, resulting in retained fragments that necessitated secondary surgical interventions. These product liability claims, consolidated under MDL No. 2974 before Judge Leigh Martin May in the U.S. District Court for the Northern District of Georgia, rest on the legal theories of design defect and failure to warn against Teva Pharmaceuticals and CooperSurgical, requiring an airtight evidentiary chain connecting the fractured polyethylene T-frame to subsequent medical injuries.

Medical device litigation can be difficult to navigate. The clumping of cases surrounding the Paragard copper IUD is a salient watershed. It marks a major shift in product liability law. 

For a while now, I have followed judicial dockets and MDL trends closely. I have also monitored agency regulations. The scope of this litigation has grown to enormous proportions. 

By August 2026, the federal docket shows over 4,150 active suits. These are all pending within MDL No. 2974. [Source: Consumer Notice]

This is now one of the largest ongoing mass torts involving medical devices. It is one of the biggest in the US court system. 

And you must understand the corporate history.

You also need to track the evolving chains of liability. These elements characterize a Paragard lawsuit claim. This understanding is the first step to properly construe the legal scope of the claim. 

What Is The Paragard Lawsuit? Understanding Mass Tort and Corporate Liability

The Paragard device – a non-hormonal, T-shaped contraceptive that utilizes copper wire to create a localized spermicidal environment – was originally developed, manufactured, and marketed by Teva Pharmaceuticals USA.

However, in a corporate transaction executed in late 2017, CooperSurgical acquired the New Drug Application (NDA) and manufacturing rights for the device for $1.1 billion.

Through my review of the master complaints filed in the Northern District of Georgia, this transition of ownership creates a dual-defendant framework.

Plaintiffs routinely sue both corporate entities.

Teva Pharmaceuticals remains highly exposed because they controlled the initial design, early manufacturing lots, and the baseline marketing strategies during the timeframe when many long-term users received their implants.

CooperSurgical faces strict post-market liability for continuing to distribute the device without modifying its instructions for use (IFU) or adding robust warning labels regarding structural degradation, despite a mounting volume of adverse event notices.

Scientific Mechanisms Of Failure And Evidentiary Triggers

A core principle of my legal research is that successful product liability claims cannot rely on vague assertions of injury; they require precise scientific exposition. The foundational argument anchoring the Paragard lawsuit centers on a distinct material and structural defect.

The base of the device consists of a polyethylene T-frame wrapped in copper wire. The primary mechanism of failure involves the structural degradation of this plastic matrix over time. As the device sits within the uterine environment, the polyethylene arms become increasingly brittle.

When a healthcare professional attempts to remove the device by pulling the attached retrieval strings according to standard clinical protocols, the brittle T-frame is incapable of withstanding the mechanical tension.

Instead of flexing and sliding smoothly through the cervical canal, one or both of the horizontal plastic arms snap off.

The resulting fragments frequently become deeply embedded within the myometrium (the muscular wall of the uterus) or, worse, perforate the uterine lining entirely and migrate into the broader pelvic cavity.

The data corroborating this failure mechanism is expansive. According to data tracked within the FDA Adverse Event Reporting System (FAERS), the device has been the subject of over 7,000 complaints tracking structural breakage, with thousands classified as highly severe. [Source: Drug Watch]

Clinical Evidence Matrix At A Glance

To illustrate how these mechanical failures map directly to required medical interventions, I have synthesized the following clinical evidence matrix:

Mechanical Failure Type	Diagnostic Indicator	Secondary Retrieval Protocol	Associated Long-Term Sequelae
In-Situ Arm Fracture	Transvaginal Ultrasound / Hysterosalpingogram	Hysteroscopy: Outpatient endoscopic visualization and micro-forceps extraction.	Localized tissue scarring, severe pelvic pain, chronic endometritis.
Deep Myometrial Embedding	Pelvic Computed Tomography (CT) / MRI	Laparoscopy: Minimally invasive abdominal surgery under general anesthesia.	Permanent structural uterine damage, elevated risk of future ectopic pregnancy.
Transuterine Perforation	Abdominal X-Ray / Diagnostic Laparoscopy	Laparotomy: Open abdominal surgery to locate and retrieve migrated plastic or copper shards.	Secondary organ puncture (bladder/intestines), internal hemorrhaging, peritonitis.
Catastrophic Fragmentation	Comprehensive Multi-Planar Imaging	Total Hysterectomy: Complete surgical removal of the uterus and cervix.	Permanent structural infertility, surgical menopause, profound psychological trauma.

Advanced Defenses In The Paragard Lawsuit

A critical hurdle in any high-stakes toxic tort or medical device action is surviving the early defensive motions filed by corporate legal teams designed to throw cases out before they ever reach a jury.

In the Paragard lawsuit, defense counsel for Teva and CooperSurgical have aggressively leveraged temporal defenses, specifically the Statute of Limitations and the Statute of Repose.

My research indicates that in early 2025, the defense successfully secured the dismissal of several state-level claims by arguing that plaintiffs waited too long to file after their initial injury occurred.

Understanding the interaction between these two doctrines is mandatory for anyone evaluating a potential claim:

The Discovery Rule (Statute Of Limitations):

Most states apply a standard two-to-three-year statute of limitations for personal injury. However, because an IUD fragment can remain silently embedded without immediate overt symptoms, qualified consumer attorneys rely heavily on the Discovery Rule.

This principle dictates that the filing clock does not begin ticking until the exact moment the plaintiff discovered – or through reasonable diligence should have discovered – that their injury was caused by the broken medical device (typically marked by the date of an ultrasound or a failed removal procedure).

The Statute Of Repose:

This represents a much more rigid legal barrier.

Unlike the statute of limitations, a statute of repose places an absolute, immutable deadline on the right to file a Paragard lawsuit based entirely on the date the product was sold or implanted, completely independent of when the injury actually manifested.

If a plaintiff lives in a state with a strict 10-year statute of repose and their Paragard was inserted 11 years ago, their claim may be legally dead before they even discover the device has fractured.

Real-Time Paragard Lawsuit Update: The Evolution Of Bellwether Trials

To evaluate the true settlement potential of these mass actions, we must look directly at the progression of the bellwether trial schedule.

Bellwether trials serve as critical test cases designed to gauge jury reactions to evidence, expert testimonies, and corporate internal documents. They provide the empirical baseline needed to shape eventual global settlement frameworks.

The litigation path has proven highly contentious. In a significant blow to the plaintiffs’ steering committee, Teva Pharmaceuticals prevailed in the first federal bellwether trial concluded in February 2026.

Following an intensive two-week trial in Atlanta, the jury rejected the plaintiff’s arguments, finding that the warnings provided to physicians were adequate under the learned intermediary doctrine.

However, mass tort veterans recognize that a single defense victory does not dismantle an entire MDL.

The litigation remains fluid, and Judge Leigh Martin May has officially entered a new scheduling order directing the next critical bellwether case – Robere v. Teva – to proceed to trial on September 28, 2026. [Source: Miller and Zois]

The outcomes of this upcoming trial, alongside potential appellate reviews before the Eleventh Circuit, will heavily influence whether the defendants opt to establish a multi-million dollar global settlement pool or continue litigating individual claims.

Tiered Analytical Framework For Paragard Lawsuit Case Valuation

Should the Paragard lawsuit shift toward an out-of-court resolution following the remaining 2026 trials, historical precedents like the Mirena IUD settlements suggest that a tiered matrix points system will govern payouts.

Payout allocations are fundamentally dependent on the severity of the injury and the invasiveness of the corrective medical treatments recorded in the official pathology reports.

The structural assessment and eventual financial valuation of a claim within MDL No. 2974 are organized under a tiered points framework. [Source: Consumer Notice]

Case worth is fundamentally determined by the severity of the internal injury and the invasiveness of the required secondary surgical intervention:

Tier 1 (Catastrophic Injury Valuation):

Reserved for plaintiffs who suffered complete uterine perforation, severe systemic pelvic inflammatory disease (PID), or migration of the copper wire into adjacent organs.

These cases require highly invasive open laparotomies or complete hysterectomies, resulting in permanent, irreversible infertility.

Tier 2 (Severe Operational Valuation):

Encompasses individuals whose devices fractured, leaving fragments that could not be retrieved in-office, thereby requiring surgical intervention via operative laparoscopy under general anesthesia to remove embedded shards from the uterine lining.

Tier 3 (Moderate Complication Valuation):

Applies to instances where fragmentation occurred, but the pieces were successfully retrieved via a standard outpatient hysteroscopy or repeated specialized in-office extraction procedures, without causing permanent, long-term organ damage or loss of reproductive capacity.

The Evidentiary Protocol For Building A Paragard Lawsuit Claim

For any consumer or legal researcher seeking to transition from general knowledge to active case construction, the primary objective is the immediate acquisition of uncontestable documentary proof.

Because the defense will aggressively challenge product identification, the plaintiff must secure their complete OB-GYN intake and explant records.

Additionally, the process includes the device identification tag. This tag comes directly from the medical chart. It contains vital information about the individual product lot batch number.

Crucially, this step confirms the device was a genuine Paragard unit. It proves the device was not a competitor’s hormonal product. Furthermore, you must obtain the surgical report. This document shows exactly why there was a failure to remove the device.

Following that, you need medical images taken after the procedure. These images include ultrasounds or CT scans.

They reveal any foreign material left behind in the body. Ultimately, these specific records form the absolute core of a valid claim.